Search

Your search keyword '"Erol Göka"' showing total 126 results

Search Constraints

Start Over You searched for: Author "Erol Göka" Remove constraint Author: "Erol Göka"
126 results on '"Erol Göka"'

Search Results

2. Evaluation of dsyfunctional attitudes, distress and discomfort tolerance levels in patients with premenstruel dysphoric disorder (tur)

3. Erkek alkol bağımlılığı hastalarında tedavi motivasyonu, bağımlılık özellikleri, aşerme ve mizaç özellikleri ilişkisi

4. A case of generalized edema associated with risperidone monotherapy

5. Pregabalin abuse among patients with opioid use disorders may increase the severity of withdrawal symptoms: a single-center, case-control study

6. The severity of dissociative symptoms among patients with cannabis and synthetic cannabinoid use disorder: association with substance use characteristics and suicide

7. Secretagogin may not be a new neuroendocrine biomarker in schizophrenia while levels may reflect clinical severity

8. Examination of formal thought disorder and its clinical correlates with the Turkish Version of the Thought and Language Disorder Scale (TALD-TR) in schizophrenia

9. Serum 15-d-PGJ2 and PPARγ levels are reduced in manic episode of bipolar disorder while IL-4 levels are not affected

10. The relationship between internalized stigma and treatment motivation, perceived social support, depression and anxiety levels in opioid use disorder

11. Oral Research Presentations

12. Symposium Oral Presentations

13. Serum glial cell line-derived neurotrophic factor levels and impulsivity in heroin addiction: a cross-sectional, case-control study of 129 heroin addicts

14. 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology

15. 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology

16. 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology

17. Reversible cycloplegia caused by duloxetine: a case report

19. Neuronal pentraxin-2 (NPTX2) serum levels during an acute psychotic episode in patients with schizophrenia

21. Association of Glial Cell-Line Derived Neurotrophic Factor and Nerve Growth Factor with Duration of Untreated Psychosis and Clinical Symptoms in Drug-Naive Schizophrenia

22. Low Anti-Mullerian Hormone Levels Are Associated with the Severity of Anxiety Experienced by Healthcare Professionals During the COVID-19 Pandemic

23. Serum concentrations of aminoacylase 1 in schizophrenia as a potential biomarker: a case-sibling-control study

24. The Social Effects of COVID-19 Pandemics

25. Evaluating the Relationship Between Post Traumatic Stress Disorder Symptoms and Psychological Resilience in a Sample of Turkoman Refugees in Turkey

26. Thiol/Disulfide Homeostasis in Bipolar and Unipolar Depression

27. Association between treatment motivation, addiction characteristics, craving and temperament traits in male patients with alcohol addiction

29. Evaluation of Anxiety, Burnout and Psychological Resilience Levels of Healthcare Workers in the COVID-19 Pandemic

30. Do Anxiety and Depression Levels Affect the Inflammation Response in Patients Hospitalized for COVID-19

31. From predictions to evidence: Treatment compliance, disease progression and social compliance of patients with schizophrenia in the COVID‐19 pandemic

32. Pregabalin abuse among patients with opioid use disorders may increase the severity of withdrawal symptoms: a single-center, case-control study

33. The severity of dissociative symptoms among patients with cannabis and synthetic cannabinoid use disorder: association with substance use characteristics and suicide

34. Secretagogin may not be a new neuroendocrine biomarker in schizophrenia while levels may reflect clinical severity

35. Sexual functions and prolactin levels in patients with bipolar disorder

36. Comparison of Formal Thought Disorder in the Acute Episode of Schizophrenia and Manic Episode of Bipolar Affective Disorder

38. Retrospective Evaluation of Cases Examined to Determine Criminal Responsibilities

39. Correction to: Galectin-1 and Galectin-3 Levels in Patients with Schizophrenia and their Unaffected Siblings

40. Multiple antipsychotics use in patients with schizophrenia: Why do we use it, what are the results from patient follow-ups?

41. Galectin-1 and Galectin-3 Levels in Patients with Schizophrenia and their Unaffected Siblings

43. Brief psychotic disorder due to ephedrine

44. Serum PGE2, 15d-PGJ, PPAR gamma and CRP levels in patients with schizophrenia

45. Serum 15-d-PGJ2 and PPARγ levels are reduced in manic episode of bipolar disorder while IL-4 levels are not affected

46. High neutrophil-lymphocyte ratio in schizophrenia independent of infectious and metabolic parameters

47. A case of generalized edema associated with risperidone monotherapy (tur)

48. Serum glial cell line-derived neurotrophic factor levels and impulsivity in heroin addiction: a cross-sectional, case-control study of 129 heroin addicts

49. Serum TNF-related weak inducer of apoptosis (TWEAK) and TNF-related apoptosis-inducing ligand (TRAIL) levels of patients with bipolar disorder in manic episode, in remission and healthy controls

50. [Effects of Nitric Oxide Synthase-1 Exon 1f-VNTR Gene Polymorphism on the Clinical Symptoms of Alcohol Dependence,Impulsivity and Comorbid Attention Deficit Hyperactivity Disorder]

Catalog

Books, media, physical & digital resources